NCT02585843View on ClinicalTrials.gov

Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Heart Failure
Interventions
DRUG

Spironolactone 100mg

2 capsules of study medication consist of 100mg, PO (oral) for 7 days

DRUG

Spironolactone 25mg

25mg/day of spironolactone

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT02585843 - Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance | Biotech Hunter | Biotech Hunter